- Shares of Cue Biopharma have tumbled some 75% since November 2021, as somewhat underwhelming data from slowly developing Phase 1 trials are at fault.
- The company’s Immuno-STAT platform is a novel approach to immuno-oncology that should reduce risks associated with systemic exposure from legacy CAR-T methodologies.
- With few catalysts until a readout from a first-line combination therapy Phase 1 trial near YE22, the recent insider buying merited a deeper dive.
- A full investment analysis follows in the paragraphs below.
For further details see:
Cue Biopharma: A First Assessment